Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

Business Leaders

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
HomeAll NewsMost read newsBusiness Leaders Biography
Portrait de Mark Alles
Age : 61
Public asset : 1,166,530 USD
Country of residence : Unknown
Linked companies : Turning Point Therapeutics, Inc. - Antengene Corporation Limited - Syros Pharmaceuticals, Inc. - Juno Therapeutics Inc

Biography of Mark Alles 
Mark J. Alles is on the board of Syros Pharmaceuticals, Inc., Juno Therapeutics, Inc., Antengene Corporation Co., Ltd. and Antengene Corp. Ltd. In the past he was Chairman, President, CEO & COO at Celgene Corp., Principal at Centocor, Inc., Principal at Bayer Corp. and Vice President-Oncology Business Unit at Aventis Pharmaceuticals, Inc. Mr. Alles received an undergraduate degree from Lock Haven University of Pennsylvania.


Current positions of Mark Alles 
Holdings of Mark Alles 
Mark Alles : Personal Network 
Most Read News 
12/05MUKESH AMBANI : Indian salesmen threaten supply disruptions in protest against Reliance
RE
11/30JACK DORSEY : Jack Dorsey chases crypto, fintech dream post Twitter
RE
12/01JACK DORSEY : Dorsey-led Square rebrands to Block in nod to blockchain
RE
12/07ELON MUSK : Tesla's Musk says Biden's electric vehicle bill should not pass Congress
RE
12/03CATHIE WOOD : Cathie Wood's ARK Innovation fund hits 13-month low in tech selloff
RE
11/26ELON MUSK : Tesla decides against state aid for German battery plant as Musk opposes subsidies
RE
12/02ELON MUSK : Musk exercises more options, sells Tesla shares worth $1.01 billion
RE
11/30Salesforce shares fall on disappointing profit forecast
RE
12/02TILMAN FERTITTA : FAST Acquisition refuses to terminate SPAC merger with Fertitta Entertainment
RE
12/03DAVID HARRISON : U.S. Nonfarm Payrolls Up 210K in November, Unemployment Rate 4.2% -- Update
DJ
More news


© 2021 People and Ownership :   
Mark Alles : Connections 


Latest news about Mark Alles 
05/25TURNING POINT THERAPEUTICS : Names Former Celgene CEO as Board Chair
MT
05/25Turning Point Therapeutics, Inc. Announces Board Changes
CI
2019BRISTOL MYERS SQUIBB : Celgene, Bristol-Myers set $2.2 billion termination fee for their mega deal
T3
2019Celgene, Bristol-Myers set $2.2 billion termination fee for their mega deal
RE
2019BRISTOL MYERS SQUIBB : Celgene, Bristol-Myers set $2.2 billion termination fee for their mega deal
T3
2019Bristol-Myers to buy Celgene for $74 billion in largest biopharma deal
RE
2019Bristol-Myers to buy Celgene for $74 billion in largest biopharma deal
RE
More news